

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

| | |
|--|--|
| In re: | Chapter 11 |
| Apple Tree Life Sciences, Inc., <i>et al.</i> , ¹ | Case No. 25-12177 (LSS) |
| Debtors. | (Jointly Administered) |
| | Hearing Date: February 13, 2026 at 10:00 a.m. (ET) |
| | Obj. Deadline: January 22, 2026 at 4:00 p.m. (ET) |

**APPLICATION OF THE DEBTORS FOR AUTHORITY TO RETAIN AND EMPLOY
KURTZMAN CARSON CONSULTANTS, LLC DBA VERITA GLOBAL
AS ADMINISTRATIVE ADVISOR EFFECTIVE AS THE PETITION DATE**

The above-captioned debtors and debtors in possession (collectively, the “Debtors”) submit the *Declaration of Evan Gershbein in Support of the Application of the Debtors for Authority to Retain and Employ Kurtzman Carson Consultants, LLC dba Verita Global as Administrative Advisor Effective as of the Petition Date*, attached hereto as **Exhibit B** (the “Gershbein Declaration”), and respectfully state as follows in support of this application (the “Application”):

RELIEF REQUESTED

The Debtors seek entry of an order, substantially in the form attached hereto as **Exhibit A** (the “Proposed Order”), pursuant to sections 327(a) and 328 of title 11 of the United States Code, (the “Bankruptcy Code”), rules 2014 and 2016 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), and rules 2014-1 and 2016-1 of the Local Rules of the United States

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); and Nine Square Therapeutics, Inc. (4503). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.



Bankruptcy Court for the District of Delaware (the “Local Rules”), (a) authorizing the Debtors to employ and retain Kurtzman Carson Consultants, LLC dba Verita Global (“Verita”) as administrative advisor (the “Administrative Advisor”) in the Debtors’ Chapter 11 Cases effective as of the December 9, 2025 Petition Date (as defined below) and (b) granting related relief.

JURISDICTION AND VENUE

1. The United States Bankruptcy Court for the District of Delaware (the “Court”) has jurisdiction over this matter pursuant to 28 U.S.C. § 1334 and the *Amended Standing Order of Reference* from the United States District Court for the District of Delaware. This is a core proceeding within the meaning of 28 U.S.C. § 157(b)(2).

2. Pursuant to Local Rule 9013-1(f), the Debtors confirm their consent to the Court entering a final order in connection with this Motion to the extent that it is later determined that the Court, absent consent of the parties, cannot enter final orders or judgments in connection herewith consistent with Article III of the United States Constitution.

3. Venue is proper under 28 U.S.C. §§ 1408 and 1409.

4. The bases for the relief requested herein are sections 327(a) and 328 of the Bankruptcy Code, Bankruptcy Rules 2014 and 2016, and Local Rules 2014-1 and 2016-1.

BACKGROUND

5. On December 9 and 15, 2025 and January 1, 2026 (the “Petition Dates”), each Debtor filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code (the “Chapter 11 Cases”). These Chapter 11 Cases are being jointly administered for procedural purposes only pursuant to Bankruptcy Rule 1015(b). *See* Docket No. 69.

6. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. No request for the

appointment of a trustee or examiner has been made in these Chapter 11 Cases, and no official committees have been appointed or designated.

7. A detailed description of the facts and circumstances of these Chapter 11 Cases is set forth in the *Declaration of Dr. Seth L. Harrison in Support of Chapter 11 Petitions and First Day Motions* [Docket No. 18] (the “Harrison Declaration”) and the *Declaration of Perry M. Mandarino, Chief Restructuring Officer of the Debtors, in Support of Chapter 11 Petitions and First Day Motions* [Docket No. 25] (the “Mandarino Declaration,” and with the Harrison Declaration, the “First Day Declarations”).² As is described in more detail in the First Day Declarations, the Debtors commenced these Chapter 11 Cases due to the failure of Rigmora Biotech Investor One LP, and Rigmora Biotech Investor Two LP (collectively, “Rigmora”) to fulfill their contractual obligations, and their attempts to wind up Debtor ATP Life Science Ventures, L.P. (the “Partnership Debtor”) and liquidate the portfolio companies. Through these Chapter 11 Cases, the Debtors seek to stabilize their business, and, under the Court’s supervision, restructure the Partnership Debtor’s capital structure.

VERITA’S RETENTION

8. The terms of retention and employment of Verita are set forth in that certain services agreement (the “Services Agreement”), annexed as Exhibit 1 to the Proposed Order, attached hereto as Exhibit A. Pursuant to this application, the Debtors seek to retain Verita to provide, among other things, the following bankruptcy administrative services (collectively, the “Administrative Services”), if and to the extent the Debtors request:

- (a) assisting with, among other things, the preparation of the Debtors’ schedules of assets and liabilities, schedules of executory contracts and unexpired leases and statements of financial affairs;

² Capitalized terms not defined herein shall have the meanings ascribed to such terms in the First Day Declarations, as applicable.

- (b) assisting with, among other things, solicitation, balloting, tabulation and calculation of votes, as well as preparing any appropriate reports required in furtherance of confirmation of any chapter 11 plan;
- (c) generating an official ballot certification and testifying, if necessary, in support of the ballot tabulation results for any chapter 11 plan(s) in the Chapter 11 Cases;
- (d) generating, providing and assisting with claims objections, exhibits, claims reconciliation, and related matters; and
- (e) providing such other claims processing, noticing, solicitation, balloting, and administrative services described in the Services Agreement, but not included in the Section 156(c) Application,³ as may be requested by the Debtors from time to time.

9. Verita has substantial experience providing the Administrative Services in numerous cases of comparable size, including several cases in this Court. *See, e.g., In re Fulcrum Bioenergy, Inc., et al.*, Case No. 24-12008 (TMH) (Bankr. D. Del. Oct. 15, 2024); *In re QLess, Inc.*, Case No. 24-11395 (BLS) (Bankr. D. Del. Aug. 19, 2024); *In re Fisker Inc., et al.*, Case No. 24-11390 (TMH) (Bankr. D. Del. Jul. 18, 2024); *In re Supply Source Enterprises, Inc., et al.*, Case No. 24-11054 (BLS) (Bankr. D. Del. Jun. 13, 2024); *In re Prosomnus, Inc., et al.*, Case No. 24-10972 (JTD) (Bankr. D. Del. Jun. 4, 2024); *In re Sticky's Holding LLC, et al.*, Case No. 24-10856 (JKS) (Bankr. D. Del. May 16, 2024); *In re SC Healthcare Holding, LLC et al.*, Case No. 24-10443 (TMH) (Bankr. D. Del. Apr. 22, 2024); *In re Cano Health, Inc., et al.*, Case No. 24-10164 (KBO) (Bankr. D. Del. Mar. 5, 2024); *In re InVivo Therapeutics Corp., et al.*, Case No. 24-10137 (MFW) (Bankr. D. Del. Feb. 22, 2024); *In re AN Global LLC, et al.*, Case No. 23-11294 (JKS) (Bankr. D. Del. Oct. 3, 2023); *In re Proterra Inc., et al.*, No. 23-11120 (BLS) (Bankr. D. Del. Sept. 5, 2023); *In re Lordstown Motors Corp., et al.*, No. 23-10831 (MFW) (Bankr. D. Del. July 25,

³ On December 15, 2025, the Debtors filed the *Debtors' Application for Entry of an Order (I) Approving the Retention and Employment of Kurtzman Carson Consultants, LLC dba Verita Global as the Claims and Noticing Agent to the Debtors and (II) Granting Related Relief* [Docket No. 22] (the "Section 156(c) Application"), seeking to retain Verita as the Debtors' claims and noticing agent pursuant to 28 U.S.C. § 156(c).

2023); *In re PGX Holdings, Inc., et al.*, No. 23-10718 (CTG) (Bankr. D. Del. July 19, 2023); *In re KDC Agribusiness LLC, et al.*, No. 23-10786 (CTG) (Bankr. D. Del. July 18, 2023); *In re PlastiQ Inc., et al.*, No. 23-10671 (BLS) (Bankr. D. Del. June 19, 2023); *In re Structurlam Mass Timber U.S., Inc., et al.*, No. 23-10497 (CTG) (Bankr. D. Del. May 25, 2023); *In re Standayne LLC, et al.*, No. 23-10207 (TMH) (Bankr. D. Del. Mar. 29, 2023); *In re Starry Group Holdings, Inc., et al.*, No. 23-10219 (KBO) (Bankr. D. Del. Mar. 21, 2023); *In re Tricida, Inc.*, Case No. 23-10024 (JTD) (Bankr. D. Del. Feb. 26, 2023); *In re Carestream Health, Inc., et al.*, Case No. 22-10778 (JKS) (Bankr. D. Del. Oct. 7, 2022); *In re First Guaranty Mortgage Corp., et al.*, Case No. 22-1058 (CTG) (Bankr. D. Del. Jul. 28, 2022); *In re Zosano Pharma Corp.*, Case No. 22-10506 (JKS) (Bankr. D. Del. June 30, 2022); *In re Sequential Brands Group, Inc., et al.*, Case No. 21-11194 (JTD) (Bankr. D. Del. Oct. 4, 2021); *In re Alex and Ani, LLC, et al.*, Case No. 21-10746 (CTG) (Bankr. D. Del. Jun. 15, 2021); *In re TECT Aerospace Group Holdings, Inc., et al.*, Case No. 21-10670 (KBO) (Bankr. D. Del. May 5, 2021); *In re JetFleet Holding Corp. (f/k/a AeroCentury Corp.)*, Case No. 21-10637 (JTD) (Bankr. D. Del. Apr. 30, 2021); *In re Medley LLC*, Case No. 21-10525 (KBO) (Bankr. D. Del. Apr. 1, 2021); *In re Chaparral Energy, Inc.*, Case No. 20-11947 (MFW) (Bank. D. Del. Sep. 10, 2020).

10. The Debtors chose Verita to perform the Administrative Services because of Verita's experience, reputation, familiarity with the Chapter 11 Cases, and the competitiveness of its fees. The Debtors submit that using Verita to provide the Administrative Services has provided, and will continue to provide, the most cost-effective and efficient administration of the Chapter 11 Cases. Further, retaining Verita to perform the Administrative Services has allowed, and will continue to allow, the Debtors and their other professionals to focus on key aspects of the Debtors' restructuring efforts. Accordingly, the Debtors believe that Verita is qualified to provide

the Administrative Services and that Verita's retention in such capacity is in the best interests of the Debtors' estates and creditors.

COMPENSATION AND DISINTERESTEDNESS

11. The fees Verita will charge in connection with its services to the Debtors are set forth in the pricing schedule attached to the Services Agreement. The Debtors respectfully submit that Verita's rates are competitive and comparable to the rates Verita's competitors charge for similar services, and are reasonable given the quality of Verita's services and Verita's bankruptcy expertise. Additionally, Verita will seek reimbursement from the Debtors for reasonable and documented expenses in accordance with the terms of the Services Agreement.

12. Verita intends to apply to the Court for allowance of compensation and reimbursement of out-of-pocket expenses incurred after the December 9, 2025 Petition Date in connection with the services that it provides as the Administrative Advisor in the Chapter 11 Cases in accordance with the applicable provisions of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules, and any other applicable orders of the Court.

13. The Gershbein Declaration represents that, to the best of its knowledge, Verita is not connected with the Debtors, their creditors, the Office of the United States Trustee for the District of Delaware (the "U.S. Trustee"), or any person employed by the U.S. Trustee and that, to the best of Verita's knowledge, after due inquiry, Verita does not by reason of any direct or indirect relationship to, connection with or interest in the Debtors, hold or represent any interest materially adverse to the Debtors, their estates or any class of creditors or equity interest holders with respect to the matters upon which it is to be engaged. Further, Verita has performed a comprehensive conflict search in connection with the Section 156(c) Application. Based upon the Gershbein Declaration, Verita is a "disinterested person," as that term is defined in section 101(14) of the Bankruptcy Code.

INDEMNIFICATION

14. As part of the overall compensation payable to Verita under the terms of the Services Agreement, the Debtors have agreed to certain indemnification and contribution obligations as set forth in the Services Agreement, to the extent permitted by applicable law and as modified in the Proposed Order.

15. The terms of the Services Agreement and indemnification provisions included therein were negotiated at arm's-length between the Debtors and Verita, and the Debtors respectfully submit that these provisions of the Services Agreement are reasonable and in the best interests of the Debtors, their estates, and their creditors. Moreover, consistent with the practice in this jurisdiction, the Debtors request, and Verita has agreed, that the Court approve the indemnification provisions reflected in the Services Agreement subject to the modifications set forth in the Proposed Order. The Debtors believe that the proposed modifications to the indemnification provisions of the Services Agreement are appropriate under the circumstances, consistent with recent orders entered in this jurisdiction and, therefore, should be approved.

BASIS FOR RELIEF

I. Retention and Employment of Verita as the Administrative Advisor is Permitted.

16. The Debtors seek approval of the employment and retention of Verita as Administrative Advisor pursuant to sections 327(a) and 328(a) of the Bankruptcy Code. Section 327(a) provides that a debtor “may employ one or more . . . professional persons, that do not hold or represent an interest adverse to the estate, and that are disinterested persons, to represent or assist” the debtor in carrying out its duties. 11 U.S.C. § 327(a).

17. In addition, section 328(a) of the Bankruptcy Code provides, in relevant part, that debtors “with the court’s approval, may employ or authorize the employment of a professional person under section 327 . . . on any reasonable terms and conditions of employment, including

on a retainer, on an hourly basis, on a fixed or percentage fee basis, or on a contingent fee basis.”

11 U.S.C. § 328(a).

18. Bankruptcy Rule 2014(a) requires that an application for retention include:

“[S]pecific facts showing (A) the need for the employment; (B) the name of the person to be employed; (C) the reasons for the selection; (D) the professional services to be rendered; (E) the proposed arrangement for compensation; and (F) to the best of the applicant’s knowledge, all the person’s connections with the debtor, creditors, any other party in interest, their respective attorneys and accountants, the United States trustee, and any person employed in the United States trustee’s office.

Fed. R. Bankr. P. 2014(a).

19. Additionally, Local Rule 2014-1 requires an entity seeking approval of employment under section 327(a) of the Bankruptcy Code to file a motion, supporting affidavit and proposed order, all of which have been satisfied by this Application, the Gershbein Declaration, and the Proposed Order. Further, in accordance with Local Rule 2014-1, Verita acknowledges its continuing duty to supplement the Gershbein Declaration with additional material information relating to the employment of Verita, if necessary.

20. In light of the size and complexity of the Chapter 11 Cases, the Debtors respectfully submit that employing and retaining Verita pursuant to the terms of the Services Agreement, as modified by the Proposed Order, is necessary and in the best interests of the Debtors’ estates and all parties in interest. The Debtors also believe that the terms and conditions of the Services Agreement, as modified by the Proposed Order are reasonable, and have been previously approved by the Court in the Section 156(c) Application. Further, Verita will comply with the applicable provisions of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules and any other procedures or orders of the Court.

II. Relief Effective as of the December 9, 2025 Petition Date is Appropriate.

21. Pursuant to the Debtors' request, Verita has agreed to serve as Administrative Advisor on and after the December 9, 2025 Petition Date with assurances that the Debtors would seek approval of its employment and retention, effective as of the December 9, 2025 Petition Date, so that Verita may be compensated for its pre-Application services. The Debtors believe that no party in interest will be prejudiced by the granting of employment as of the December 9, 2025 Petition Date, as provided in this Application, because Verita has provided, and continues to provide, valuable services to the Debtors' estates during the interim period. Further, courts in this district have routinely approved retroactive employment effective as of a date certain, similar to that requested herein, in matters comparable to this matter.

22. Accordingly, to help manage administrative tasks with respect to the numerous notice parties that are expected to be involved in the Chapter 11 Cases, and the complexity of such cases, the Debtors respectfully request entry of an order authorizing the Debtors to employ and retain Verita as Administrative Advisor effective as of the December 9, 2025 Petition Date.

NOTICE

23. The Debtors will provide notice of this Motion to the following parties and/or their respective counsel, as applicable: (a) the United States Trustee for the District of Delaware; (b) the holders of the 30 largest unsecured claims against the Debtors (on a consolidated basis); (c) the United States Attorney's Office for the District of Delaware; (d) the Internal Revenue Service; (e) the attorneys general in the states where the Debtors conduct their business operations; and (f) any party that has requested notice pursuant to Bankruptcy Rule 2002. The Debtors submit that, in light of the nature of the relief requested, no other or further notice need be given.

NO PRIOR REQUEST

24. No prior request for the relief sought in this Application has been made to this or any other court.

WHEREFORE, the Debtors respectfully request that the Court enter the Proposed Order, substantially in the form attached hereto as **Exhibit A**, granting the relief requested herein and such other and further relief as the Court may deem proper.

Dated: January 8, 2026
Wilmington, Delaware

Respectfully submitted,

/s/ Perry M. Mandarino
Perry M. Mandarino
Chief Restructuring Officer to the Debtors and
Debtors in possession

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Apple Tree Life Sciences, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-12177 (LSS)

(Jointly Administered)

Hearing Date: February 13, 2026 at 10:00 a.m. (ET)

Objection Deadline: January 22, 2026 at 4:00 p.m. (ET)

**NOTICE OF APPLICATION OF THE DEBTORS FOR AUTHORITY TO RETAIN
AND EMPLOY KURTZMAN CARSON CONSULTANTS, LLC DBA VERITA GLOBAL
AS ADMINISTRATIVE ADVISOR EFFECTIVE AS OF THE PETITION DATE**

PLEASE TAKE NOTICE that the above-captioned debtors and debtors in possession (the “Debtors”), filed the *Application of the Debtors for Authority to Retain and Employ Kurtzman Carson Consultants, LLC dba Verita Global as Administrative Advisor Effective as of the Petition Date* (the “Application”) with the United States Bankruptcy Court for the District of Delaware (the “Court”).

PLEASE TAKE FURTHER NOTICE that objections to the Application, if any, must be in writing, filed with the Clerk of the United States Bankruptcy Court for the District of Delaware, 3rd Floor, 824 N. Market Street, Wilmington, Delaware 19801, on or before **January 22, 2026 at 4:00 p.m. (ET)** (the “Objection Deadline”), and served upon and received by the undersigned proposed counsel for the Debtors.

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); and Nine Square Therapeutics, Inc. (4503). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

PLEASE TAKE FURTHER NOTICE that, if any objections to the Application are received, the Application and such objections shall be considered at a hearing before the Honorable Laurie Selber Silverstein at the Bankruptcy Court, 824 N. Market Street, 6th Floor, Courtroom No. 2, Wilmington, Delaware 19801 on **February 13, 2026 at 10:00 a.m. (ET)**.

IF NO OBJECTIONS TO THE APPLICATION ARE TIMELY FILED, SERVED AND RECEIVED IN ACCORDANCE WITH THIS NOTICE, THE COURT MAY GRANT THE RETENTION AND RELIEF REQUESTED IN THE APPLICATION WITHOUT FURTHER NOTICE OR HEARING.

[Remainder of Page Intentionally Left Blank]

Dated: January 8, 2026
Wilmington, Delaware

Andrew M. Berdon, Esq. (admitted *pro hac vice*)
Patricia B. Tomasco, Esq. (admitted *pro hac vice*)
Rachel E. Epstein, Esq. (admitted *pro hac vice*)
Alain Jaquet, Esq. (admitted *pro hac vice*)
Rachel Harrington, Esq. (admitted *pro hac vice*)
**QUINN EMANUEL URQUHART
& SULLIVAN, LLP**
295 5th Avenue, 9th Floor
New York, New York 10016
Telephone: (212) 849-7000
Facsimile: (212) 849-7100
Email: andrewberdon@quinnemanuel.com
pattytomasco@quinnemanuel.com
rachelepstein@quinnemanuel.com
alainjaquet@quinnemanuel.com
rachelharrington@quinnemanuel.com

-and-

Eric D. Winston, Esq. (admitted *pro hac vice*)
Razmig Izakelian, Esq. (admitted *pro hac vice*)
Benjamin Roth, Esq. (admitted *pro hac vice*)
**QUINN EMANUEL URQUHART
& SULLIVAN, LLP**
865 S. Figueroa Street, 10th Floor
Los Angeles, California 90017
Telephone: (213) 443-3000
Facsimile: (213) 443-3100
Email: ericwinston@quinnemanuel.com
razmigizakelian@quinnemanuel.com
benroth@quinnemanuel.com

Respectfully submitted,

/s/ Brett M. Haywood

L. Katherine Good (No. 5101)
Brett M. Haywood (No. 6166)
Shannon A. Forshay (No. 7293)
Ethan H. Sulik (No. 7270)
POTTER ANDERSON & CORROON LLP
1313 N. Market Street, 6th Floor
Wilmington, Delaware 19801
Telephone: (302) 984-6000
Facsimile: (302) 658-1192
Email: kgood@potteranderson.com
bhaywood@potteranderson.com
sforshay@potteranderson.com
esulik@potteranderson.com

Proposed Counsel to the Debtors and Debtors in Possession

EXHIBIT A

Proposed Order

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

| | |
|--|-------------------------|
| In re: | Chapter 11 |
| Apple Tree Life Sciences, Inc., <i>et al.</i> , ¹ | Case No. 25-12177 (LSS) |
| Debtors. | (Jointly Administered) |
| | Re: Docket No. |

**ORDER GRANTING APPLICATION OF THE
DEBTORS FOR AUTHORITY TO RETAIN AND EMPLOY
KURTZMAN CARSON CONSULTANTS, LLC DBA VERITA GLOBAL
AS ADMINISTRATIVE ADVISOR EFFECTIVE AS OF THE PETITION DATE**

Upon the application (the “Application”)² of the above-captioned debtors and debtors in possession (collectively, the “Debtors”) for entry of an order (this “Order”) for authority to employ and retain Kurtzman Carson Consultants, LLC dba Verita Global (“Verita”) as their Administrative Advisor in the Debtors’ Chapter 11 Cases, effective as of the December 9, 2025 Petition Date, as more fully described in the Application; and upon the Gershbein Declaration; and this Court having jurisdiction over this matter pursuant to 28 U.S.C. §§ 157 and 1334 and the *Amended Standing Order of Reference from the United States District Court for the District of Delaware*, dated February 29, 2012; and the Debtors having consented to entry of a final order; and this Court having found that venue of this proceeding and the Application in this district is proper pursuant to 28 U.S.C. §§ 1408 and 1409; and this Court having found that the relief requested in the Application is in the best interests of the Debtors’ estates, their creditors, and other

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); and Nine Square Therapeutics, Inc. (4503). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

² All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Application.

parties in interest; and this Court having found that the Debtors' notice of the Application and opportunity for a hearing on the Application were appropriate under the circumstances and no other notice need be provided; and this Court having reviewed the Application and having heard the statements in support of the relief requested therein at a hearing before this Court (the "Hearing"); and this Court having determined that the legal and factual bases set forth in the Application and at the Hearing establish just cause for the relief granted herein; and upon all of the proceedings had before this Court; and after due deliberation and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT

1. The Application is GRANTED as set forth herein.
2. The Debtors are authorized under section 327(a) of the Bankruptcy Code to employ and retain Verita as their Administrative Advisor in accordance with the terms set forth in the Application and the Services Agreement effective as of the December 9, 2025 Petition Date. Notwithstanding the terms of the Services Agreement, attached hereto as **Exhibit 1**, the Application is approved solely as set forth in this Order.
3. Verita is authorized to perform the Administrative Services described in the Application and set forth in the Application and the Services Agreement, and to take such other action to comply with all duties set forth in the Application and the Services Agreement.
4. In addition to the services set forth in the Application and the Services Agreement, Verita is authorized to provide other bankruptcy administration services as the Debtors and the Clerk of the Court may request from time to time.
5. Verita shall apply to the Court for allowance of compensation and reimbursement of expenses incurred after the December 9, 2025 Petition Date in accordance with the applicable

provisions of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules and any orders entered in the Chapter 11 Cases regarding professional compensation and reimbursement of expenses.

6. The Debtors shall indemnify Verita under the terms of the Services Agreement, as modified pursuant to this Order:

- a. The Indemnified Parties shall not be entitled to indemnification, contribution, or reimbursement pursuant to the Services Agreement for services, as provided under the Services Agreement, unless such services and the indemnification, contribution, or reimbursement therefore is approved by this Court.
- b. Notwithstanding anything to the contrary in the Services Agreement, the Debtors shall have no obligation to indemnify Indemnified Parties, or provide contribution or reimbursement to Indemnified Parties, for any losses, claims, damages, judgments, liabilities, or expense that are either: (a) judicially determined (the determination having become final) to have arisen from such Indemnified Parties' gross negligence, willful misconduct, or fraud; (b) for a contractual dispute in which the Debtors allege the breach of such Indemnified Parties' contractual obligations, if this Court determines that indemnification, contribution, or reimbursement would not be permissible pursuant to applicable law; or (c) settled prior to a judicial determination under subsection (a) or (b), but determined by this Court, after notice and a hearing, to be a claim or expense for which such Indemnified Parties should not receive indemnity, contribution, or reimbursement under the terms of the Services Agreement as modified by this Order.
- c. If, before the earlier of: (a) the entry of an order confirming a chapter 11 plan in these Chapter 11 Cases (that order having become a final order no longer subject to appeal); and (b) the entry of an order closing these Chapter 11 Cases, the Indemnified Parties believe that it is entitled to the payment of any amounts by the Debtors on account of the Debtors' indemnification, contribution, or reimbursement obligations under the Services Agreement (as modified by this Order), including, without limitation, the advancement of defense costs, the Indemnified Parties must file an application in this Court, and the Debtors may not pay any such amounts to the Indemnified Parties before the entry of an order by this Court approving such application and the payment requested therein. This paragraph is intended only to specify the period of time under which this Court shall have jurisdiction over any request for fees and expenses by the Indemnified Parties for indemnification, contribution, or reimbursement, and not a provision limiting the duration of the Debtors' obligation to indemnify the Indemnified Parties. All parties in interest shall retain the right to object to

any demand by the Indemnified Parties for indemnification, contribution, or reimbursement.

7. The Debtors and Verita are authorized to take all steps necessary or appropriate to carry out this Order.

8. In the event of any inconsistency between the Services Agreement, the Application, and this Order, the terms of this Order shall govern.

9. Notice of the Application as provided therein shall be deemed good and sufficient notice of such Application and the requirements of Bankruptcy Rule 6004(a) and the Local Rules are satisfied by such notice.

10. Notwithstanding any term in the Services Agreement to the contrary, this Court shall retain exclusive jurisdiction to hear and determine all matters arising from or related to the implementation, interpretation, or enforcement of this Order.

EXHIBIT 1

Services Agreement



VERITA AGREEMENT FOR SERVICES

This Agreement is entered into as of the 12 day of December 2025, between Apple Tree Life Sciences, Inc. (together with its affiliates and subsidiaries, the “Company”),¹ and Kurtzman Carson Consultants, LLC dba Verita Global (together with its affiliates and subcontractors, “Verita”). In consideration of the premises set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

Terms and Conditions

I. SERVICES

A. Verita agrees to provide the Company with consulting services regarding noticing, claims management and reconciliation, plan solicitation, balloting, disbursements and any other services agreed upon by the parties or otherwise required by applicable law, government regulations or court rules or orders.

B. Verita further agrees to provide (i) computer software support and training in the use of the support software, (ii) Verita’s standard reports as well as consulting and programming support for the Company requested reports, (iii) program modifications, (iv) data base modifications, and/or (v) other features and services in accordance with the fees outlined in a pricing schedule provided to the Company (the “Verita Fee Structure”).

C. Without limiting the generality of the foregoing, Verita may, upon request by the Company, (i) provide a communications plan including, but not limited to, preparation of communications materials, dissemination of information and a call center staffed by Verita and/or (ii) provide confidential on-line workspaces or virtual data rooms and publish documents to such workspaces or data rooms (which publication shall not be deemed to violate the confidentiality provisions of this Agreement).

D. The price listed for each service in the Verita Fee Structure represents a bona fide proposal for such services, which may be accepted in whole or in part. Services will be provided when requested by the Company or required by applicable law, government regulations or court rules or orders. Services are mutually exclusive and are deemed delivered and accepted by the Company when provided by Verita.

E. The Company acknowledges and agrees that Verita will often take direction from the Company’s representatives, employees, agents and/or professionals (collectively, the “Company Parties”) with respect to the services being provided under this Agreement. The parties agree that Verita may rely upon, and the Company agrees to be bound by, any requests, advice or information provided by the Company Parties to the same extent as if such requests, advice or information were provided by the Company. The Company agrees and understands that Verita shall not provide the Company or any other party with any legal advice.

II. PRICES, CHARGES AND PAYMENT

A. Verita agrees to charge and the Company agrees to pay Verita for its services at the rates and prices set by Verita that are in effect as of the date of this Agreement and in accordance with the Verita Fee Structure. Verita’s prices are generally adjusted periodically to reflect changes in the business and economic environment and are inclusive of all charges. Verita reserves the right to reasonably increase its

¹ The term Company shall include, to the extent applicable, the Company, as debtor and debtor in possession in its chapter 11 case, together with any affiliated debtors and debtors in possession whose chapter 11 cases are jointly administered with the Company’s chapter 11 case.



VERITA AGREEMENT FOR SERVICES

prices, charges and rates; provided, however, that if any such increase exceeds 15%, Verita will give thirty (30) days written notice to the Company.

B. In addition to fees and charges for services, the Company agrees to pay Verita's reasonable transportation, lodging, and meal expenses incurred in connection with services provided under this Agreement.

C. In addition to all fees for services and expenses hereunder, the Company shall pay to Verita (i) any fees and charges related to, arising out of, or as a result of any error or omission made by the Company or the Company Parties, as mutually determined by Verita and the Company, and (ii) all taxes that are applicable to this Agreement or that are measured by payments made under this Agreement and are required to be collected by Verita or paid by Verita to a taxing authority.

D. Where the Company requires services that are unusual or beyond the normal business practices of Verita, or are otherwise not provided for in the Verita Fee Structure, the cost of such services shall be charged to the Company at a competitive rate.

E. Verita agrees to submit its invoices to the Company monthly and the Company agrees that the amount invoiced is due and payable upon the Company's receipt of the invoice. Verita's invoices will contain reasonably detailed descriptions of charges for both hourly (fees) and non-hourly (expenses) case specific charges. Where total invoice amounts are expected to exceed \$10,000 in any single month and Verita reasonably believes it will not be paid, Verita may require advance payment from the Company due and payable upon demand and prior to the performance of services hereunder. If any amount is unpaid as of thirty (30) days from the receipt of the invoice, the Company further agrees to pay a late charge, calculated as two and one-half percent (2-1/2%) of the total amount unpaid every thirty (30) days. In the case of a dispute in the invoice amount, the Company shall give written notice to Verita within ten (10) days of receipt of the invoice by the Company. The undisputed portion of the invoice will remain due and payable immediately upon receipt of the invoice. Late charges shall not accrue on any amounts in dispute or any amounts unable to be paid due to Court order or applicable law. Unless otherwise agreed to in writing, the fees for print notice and media publication (including commissions) must be paid at least three (3) days in advance of those fees and expenses being incurred.

F. In the event that the Company files for protection pursuant to chapter 11 of the United States Bankruptcy Code (a "Chapter 11 Filing"), the parties intend that Verita shall be employed pursuant to 28 U.S.C. § 156(c) to the extent possible and otherwise in accordance with applicable Bankruptcy law and that all amounts due under this Agreement shall, to the extent possible, be paid as administrative expenses of the Company's chapter 11 estate. As soon as practicable following a Chapter 11 Filing (and otherwise in accordance with applicable law and rules and orders of the Bankruptcy Court), the Company shall cause pleadings to be filed with the Bankruptcy Court seeking entry of an order or orders approving this Agreement (the "Retention Order"). The form and substance of the pleadings and the Retention Order shall be reasonably acceptable to Verita. If any Company chapter 11 case converts to a case under chapter 7 of the Bankruptcy Code, Verita will continue to be paid for its services in accordance with the terms of this Agreement. The parties recognize and agree that if there is a conflict between the terms of this Agreement and the terms of the Retention Order, the terms of the Retention Order shall govern during the chapter 11 or other proceeding.

G. [reserved].



VERITA AGREEMENT FOR SERVICES

III. RIGHTS OF OWNERSHIP

A. The parties understand that the software programs and other materials furnished by Verita pursuant to this Agreement and/or developed during the course of this Agreement by Verita are the sole property of Verita. The term "program" shall include, without limitation, data processing programs, specifications, applications, routines, and documentation. The Company agrees not to copy or permit others to copy the source code from the support software or any other programs or materials furnished pursuant to this Agreement.

B. The Company further agrees that any ideas, concepts, know-how or techniques relating to data processing or Verita's performance of its services developed or utilized during the term of this Agreement by Verita shall be the exclusive property of Verita. Fees and expenses paid by the Company do not vest in the Company any rights in such property, it being understood that such property is only being made available for the Company's use during and in connection with the services provided by Verita under this Agreement.

IV. NON-SOLICITATION

The Company agrees that neither it nor its subsidiaries or other affiliated companies shall directly or indirectly solicit for employment, employ or otherwise retain employees of Verita during the term of this Agreement and for a period of twelve (12) months after termination of this Agreement unless Verita provides prior written consent to such solicitation or retention.

V. CONFIDENTIALITY

Each of Verita and the Company, on behalf of themselves and their respective employees, agents, professionals and representatives, agrees to keep confidential all non-public records, systems, procedures, software and other information received from the other party in connection with the services provided under this Agreement; provided, however, that if either party reasonably believes that it is required to produce any such information by order of any governmental agency or other regulatory body it may, upon not less than five (5) business days' written notice to the other party, release the required information.

VI. SUSPENSION OF SERVICE AND TERMINATION

A. This Agreement shall remain in force until terminated or suspended by either party (i) upon thirty (30) days' written notice to the other party or (ii) immediately upon written notice for Cause (defined herein). As used herein, the term "Cause" means (i) gross negligence or willful misconduct of Verita that causes serious and material harm to the Company's reorganization under chapter 11 of the Bankruptcy Code, (ii) the failure of the Company to pay Verita invoices for more than sixty (60) days from the date of invoice, or (iii) the accrual of invoices or unpaid services in excess of the retainer held by Verita where Verita reasonably believes it will not be paid.

B. In the event that this contract is terminated, regardless of the reason for such termination, Verita shall coordinate with the Company and, to the extent applicable, the clerk of the Bankruptcy Court, to maintain an orderly transfer of record keeping functions and Verita shall provide all necessary staff, services and assistance required for an orderly transfer. The Company agrees to pay for such services in accordance with Verita's then existing prices for such services. If such termination occurs following entry of the Retention Order, the Company shall immediately seek entry of an order (in form and substance reasonably acceptable to Verita) that discharges Verita from service and responsibility in the Company's bankruptcy case.



VERITA AGREEMENT FOR SERVICES

C. Any data, programs, storage media or other materials furnished by the Company to Verita or received by Verita in connection with the services provided under the terms of this Agreement may be retained by Verita until the services provided are paid for, or until this Agreement is terminated with the services paid in full. The Company shall remain liable for all fees and expenses imposed under this Agreement as a result of data or physical media maintained or stored by Verita. Verita shall dispose of the data and media in the manner requested by the Company. The Company agrees to pay Verita for reasonable expenses incurred as a result of the disposition of data or media. If the Company has not utilized Verita's services under this Agreement for a period of at least ninety (90) days, Verita may dispose of the data or media, and be reimbursed by the Company for the expense of such disposition, after giving the Company thirty (30) days' notice. Notwithstanding any term herein to the contrary, following entry of the Retention Order, the disposition of any data or media by Verita shall be in accordance with any applicable instructions from the clerk of the Bankruptcy Court, local Bankruptcy Court rules and orders of the Bankruptcy Court.

VII. SYSTEM IMPROVEMENTS

Verita strives to provide continuous improvements in the quality of service to its clients. Verita, therefore, reserves the right to make changes in operating procedure, operating systems, programming languages, general purpose library programs, application programs, time period of accessibility, types of terminal and other equipment and the Verita data center serving the Company, so long as any such changes do not materially interfere with ongoing services provided to the Company in connection with the Company's chapter 11 case.

VIII. BANK ACCOUNTS

At the Company's request and subject to Court approval following any chapter 11 filing, Verita may be authorized to establish accounts with financial institutions in the name of and as agent for the Company. To the extent that certain financial products are provided to the Company pursuant to Verita's agreement with financial institutions, Verita may receive compensation from such financial institutions for the services Verita provides pursuant to such agreement.

IX. LIMITATIONS OF LIABILITY AND INDEMNIFICATION

A. The Company shall indemnify and hold Verita, its affiliates, members, directors, officers, employees, consultants, subcontractors and agents (collectively, the "Indemnified Parties") harmless, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, judgments, liabilities and expenses (including reasonable counsel fees and expenses) (collectively, "Losses") resulting from, arising out of or related to Verita's performance under this Agreement. Such indemnification shall exclude Losses resulting from Verita's gross negligence or willful misconduct. Without limiting the generality of the foregoing, Losses include any liabilities resulting from claims by any third-parties against any Indemnified Party. The Company shall notify Verita in writing promptly upon the assertion, threat or commencement of any claim, action, investigation or proceeding that the Company becomes aware of with respect to the services provided by Verita under this Agreement. The Company's indemnification obligations hereunder shall survive the termination of this Agreement.

B. Except as provided herein, Verita's liability to the Company or any person making a claim through or under the Company for any Losses of any kind, even if Verita has been advised of the possibility of such Losses, whether direct or indirect and unless due to gross negligence or willful misconduct of Verita, shall be limited to the total amount billed or billable to the Company for the portion of the particular work which gave rise to the alleged Loss. In no event shall Verita be liable for any indirect, special or consequential



VERITA AGREEMENT FOR SERVICES

damages such as loss of anticipated profits or other economic loss in connection with or arising out of the services provided for in this Agreement. In no event shall Verita's liability to the Company for any Losses, whether direct or indirect, arising out of this Agreement exceed the total amount billed to the Company and actually paid to Verita for the services contemplated under the Agreement; provided, however, that this limitation shall not apply to the Company during any chapter 11 case in which the Company is a debtor.

C. The Company is responsible for the accuracy of the programs, data and information it or any Company Party submits for processing to Verita and for the output of such information. Verita does not verify information provided by the Company and, with respect to the preparation of schedules and statements, all decisions are at the sole discretion and direction of the Company. The Company reviews and approves all schedules and statements filed on behalf of, or by, the Company; Verita bears no responsibility for the accuracy or contents therein. The Company agrees to initiate and maintain backup files that would allow the Company to regenerate or duplicate all programs and data submitted by the Company to Verita.

D. The Company agrees that except as expressly set forth herein, Verita makes no representations or warranties, express or implied, including, but not limited to, any implied or express warranty of merchantability, fitness or adequacy for a particular purpose or use, quality, productiveness or capacity.

X. FORCE MAJEURE

Verita will not be liable for any delay or failure in performance when such delay or failure arises from circumstances beyond its reasonable control, including without limitation acts of God, acts of government in its sovereign or contractual capacity, acts of public enemy or terrorists, acts of civil or military authority, war, riots, civil strife, terrorism, blockades, sabotage, rationing, embargoes, epidemics, pandemics, outbreaks of infectious diseases or any other public health crises, earthquakes, fire, flood, other natural disaster, quarantine or any other employee restrictions, power shortages or failures, utility or communication failure or delays, labor disputes, strikes, or shortages, supply shortages, equipment failures, or software malfunctions.

XI. INDEPENDENT CONTRACTORS

The Company and Verita are and shall be independent contractors of each other and no agency, partnership, joint venture or employment relationship shall arise, directly or indirectly, as a result of this Agreement.

XII. NOTICES

All notices and requests in connection with this Agreement shall be given or made upon the respective parties in writing and shall be deemed as given as of the third day following the day it is deposited in the U.S. Mail, postage pre-paid or on the day it is given if sent by facsimile or electronic mail or on the day after the day it is sent if sent by overnight courier to the appropriate address set forth below:

KCC/Verita Global, LLC
222 N. Pacific Coast Highway, 3rd Floor
El Segundo, CA 90245
Attn: Drake D. Foster
Tel: (310) 823-9000
Fax: (310) 823-9133
E-Mail: dfoster@veritaglobal.com

Apple Tree Life Sciences, Inc.
230 Park Avenue, Suite 2800 New York, NY 10169
Attn: Perry Mandarino
Tel: (646) 367-2402
Fax:
E-Mail: pmandarino@brileysecurities.com



VERITA AGREEMENT FOR SERVICES

Or to such other address as the party to receive the notice or request so designates by written notice to the other.

XIII. APPLICABLE LAW

The validity, enforceability, and performance of this Agreement shall be governed by and construed in accordance with the laws of the State of California.

XIV. ENTIRE AGREEMENT/ MODIFICATIONS

Each party acknowledges that it has read this Agreement, understands it, and agrees to be bound by its terms and further agrees that it is the complete and exclusive statement of the agreement between the parties, which supersedes and merges all prior proposals, understandings, other agreements, and communications oral and written between the parties relating to the subject matter of this Agreement. The Company represents that it has the authority to enter into this Agreement, and the Agreement is non-dischargeable under any applicable statute or law. If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. This Agreement may be modified only by a written instrument duly executed by an authorized representative of the Company and an officer of Verita.

XV. COUNTERPARTS; EFFECTIVENESS

This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. This Agreement will become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties, which delivery may be made by exchange of copies of the signature page by facsimile or electronic mail.

XVI. ASSIGNMENT

This Agreement and the rights and duties hereunder shall not be assignable by the parties hereto except upon written consent of the other, with the exception that this Agreement can be assigned without written consent by Verita to a wholly-owned subsidiary or affiliate of Verita.

XVII. ATTORNEYS' FEES

In the event that any legal action, including an action for declaratory relief, is brought to enforce the performance or interpret the provisions of this Agreement, the parties agree to reimburse the prevailing party's reasonable attorneys' fees, court costs, and all other related expenses, which may be set by the court in the same action or in a separate action brought for that purpose, in addition to any other relief to which the prevailing party may be entitled.

EXHIBIT B

Gershbein Declaration

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

| | |
|--|---|
| In re: Apple Tree Life Sciences, Inc., <i>et al.</i> , ¹ Debtors. | Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered) |
|--|---|

**DECLARATION OF EVAN GERSHBEIN IN SUPPORT OF THE
APPLICATION OF THE DEBTORS FOR AUTHORITY TO RETAIN AND EMPLOY
KURTZMAN CARSON CONSULTANTS, LLC DBA VERITA GLOBAL AS
ADMINISTRATIVE ADVISOR EFFECTIVE AS THE PETITION DATE**

I, Evan Gershbein, being duly sworn, state the following under penalty of perjury:

1. I am an Executive Vice President of Corporate Restructuring Services for Kurtzman Carson Consultants, LLC dba Verita Global (“Verita”), whose offices are located at 222 N. Pacific Coast Highway, 3rd Floor, El Segundo, California 90245. Except as otherwise noted, I have personal knowledge of the matters set forth herein, and if called and sworn as a witness, I could and would testify competently thereto.

2. This declaration (this “Declaration”) is made in support of the *Application of the Debtors for Authority to Retain and Employ Kurtzman Carson Consultants, LLC dba Verita Global as Administrative Advisor Agent Effective as of the Petition Date* (the “Application”).²

3. This Declaration incorporates the *Declaration of Evan Gershbein in Support of Debtors’ Application for Entry of an Order (I) Approving the Retention and Employment of*

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); and Nine Square Therapeutics, Inc. (4503). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

² Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Application.

Kurtzman Carson Consultants, LLC dba Verita Global as the Claims and Noticing Agent to the Debtors and (II) Granting Related Relief, attached as Exhibit B to the Section 156(c) Application [Docket No. 22].

4. As Administrative Advisor, Verita will perform the Administrative Services specified in the Application and the Services Agreement.

5. Verita is one of the country's leading chapter 11 administrators, with experience in notice, claims administration, solicitation, balloting, and facilitating other administrative aspects of chapter 11 cases. Verita has provided the Administrative Services and has acted as the notice and claims agent in numerous cases of comparable size in this district. Verita has substantial experience providing the Administrative Services in numerous cases of comparable size, including several cases in this Court. *See, e.g., In re Fulcrum Bioenergy, Inc., et al.*, Case No. 24-12008 (TMH) (Bankr. D. Del. Oct. 15, 2024); *In re QLess, Inc.*, Case No. 24-11395 (BLS) (Bankr. D. Del. Aug. 19, 2024); *In re Fisker Inc., et al.*, Case No. 24-11390 (TMH) (Bankr. D. Del. Jul. 18, 2024); *In re Supply Source Enterprises, Inc., et al.*, Case No. 24-11054 (BLS) (Bankr. D. Del. Jun. 13, 2024); *In re Prosomnus, Inc., et al.*, Case No. 24-10972 (JTD) (Bankr. D. Del. Jun. 4, 2024); *In re Sticky's Holding LLC, et al.*, Case No. 24-10856 (JKS) (Bankr. D. Del. May 16, 2024); *In re SC Healthcare Holding, LLC et al.*, Case No. 24-10443 (TMH) (Bankr. D. Del. Apr. 22, 2024); *In re Cano Health, Inc., et al.*, Case No. 24-10164 (KBO) (Bankr. D. Del. Mar. 5, 2024); *In re InVivo Therapeutics Corp., et al.*, Case No. 24-10137 (MFW) (Bankr. D. Del. Feb. 22, 2024); *In re AN Global LLC, et al.*, Case No. 23-11294 (JKS) (Bankr. D. Del. Oct. 3, 2023); *In re Proterra Inc., et al.*, No. 23-11120 (BLS) (Bankr. D. Del. Sept. 5, 2023); *In re Lordstown Motors Corp., et al.*, No. 23-10831 (MFW) (Bankr. D. Del. July 25, 2023); *In re PGX Holdings, Inc., et al.*, No. 23-10718 (CTG) (Bankr. D. Del. July 19, 2023); *In re KDC Agribusiness LLC, et al.*, No. 23-10786 (CTG)

(Bankr. D. Del. July 18, 2023); *In re PlastiQ Inc., et al.*, No. 23-10671 (BLS) (Bankr. D. Del. June 19, 2023); *In re Structurlam Mass Timber U.S., Inc., et al.*, No. 23-10497 (CTG) (Bankr. D. Del. May 25, 2023); *In re Standayne LLC, et al.*, No. 23-10207 (TMH) (Bankr. D. Del. Mar. 29, 2023); *In re Starry Group Holdings, Inc., et al.*, No. 23-10219 (KBO) (Bankr. D. Del. Mar. 21, 2023); *In re Tricida, Inc.*, Case No. 23-10024 (JTD) (Bankr. D. Del. Feb. 26, 2023); *In re Carestream Health, Inc., et al.*, Case No. 22-10778 (JKS) (Bankr. D. Del. Oct. 7, 2022); *In re First Guaranty Mortgage Corp., et al.*, Case No. 22-1058 (CTG) (Bankr. D. Del. Jul. 28, 2022); *In re Zosano Pharma Corp.*, Case No. 22-10506 (JKS) (Bankr. D. Del. June 30, 2022); *In re Sequential Brands Group, Inc., et al.*, Case No. 21-11194 (JTD) (Bankr. D. Del. Oct. 4, 2021); *In re Alex and Ani, LLC, et al.*, Case No. 21-10746 (CTG) (Bankr. D. Del. Jun. 15, 2021); *In re TECT Aerospace Group Holdings, Inc., et al.*, Case No. 21-10670 (KBO) (Bankr. D. Del. May 5, 2021); *In re JetFleet Holding Corp. (f/k/a AeroCentury Corp.)*, Case No. 21-10637 (JTD) (Bankr. D. Del. Apr. 30, 2021); *In re Medley LLC*, Case No. 21-10525 (KBO) (Bankr. D. Del. Apr. 1, 2021); *In re Chaparral Energy, Inc.*, Case No. 20-11947 (MFW) (Bank. D. Del. Sep. 10, 2020).

6. Verita is a “disinterested person” as that term is defined in section 101(14) of the Bankruptcy Code, as modified by section 1107(b) of the Bankruptcy Code, in that Verita and its professional personnel:

- (a) are not creditors, equity security holders, or insiders of the Debtors;
- (b) are not and were not, within two years before the date of the filing of the Chapter 11 Cases, directors, officers, or employees of the Debtors; and
- (c) do not have an interest materially adverse to the interest of the Debtors’ estates or of any class of creditors or equity security holders, by reason of any direct or indirect relationship to, connection with or interest in the, the Debtors.

7. I have caused to be submitted for review by our conflicts system the names of identified potential parties in interest in these Chapter 11 Cases (the “Potential Parties in Interest”).

The list of Potential Parties in Interest was provided by the Debtors and is attached hereto as **Exhibit 1**. Verita is not aware of any relationship that would present a disqualifying conflict of interest.

8. The Debtors have many creditors and, accordingly, Verita may have rendered and may continue to render services to certain of these creditors in matters unrelated to the Chapter 11 Cases, either as vendors or in cases where Verita serves in a neutral capacity as a bankruptcy claims and noticing agent or class action settlement administrator. Verita has not and will not represent the separate interests of any such creditor in the Chapter 11 Cases. To the best of my knowledge, neither Verita, nor any of its professional personnel, has any relationship with the Debtors that would impair Verita's ability to serve as Notice and Claims Agent or Administrative Advisor. Verita has working relationships with certain of the professionals retained by the Debtors and other parties herein, but such relationships, except to the extent that Verita and counsel to the Debtors have communicated concerning the preparations for the Chapter 11 Cases, are unrelated to the Chapter 11 Cases. In addition, Verita personnel may have relationships with some of the Debtors' creditors. Such relationships are, however, of a personal or financial nature and are unrelated to the Chapter 11 Cases. Verita has and will continue to represent clients in matters unrelated to the Chapter 11 Cases and has and will continue to have relationships in the ordinary course of its business with certain vendors and professionals in connection with matters unrelated to the Chapter 11 Cases.

9. To the best of my knowledge, and except as disclosed herein and in the Section 156(c) Application, Verita neither holds nor represents any interest materially adverse to the Debtors' estates and it is a "disinterested person" within the meaning of section 101(14) of the Bankruptcy Code, as would be required by section 327(a) of the Bankruptcy Code. Verita has

performed a comprehensive conflicts check in connection with the Section 156(c) Application and will continue to supplement its disclosure to the Court if any facts or circumstances are discovered that would require disclosure.

10. On May 1, 2023, funds affiliated with GCP Capital Partners LLC (“GCP”) indirectly acquired a controlling equity interest in Verita (the “Acquisition”). Pursuant to the Acquisition, an indirect, non-controlling, beneficial minority interest in Verita was acquired by funds affiliated with J.P. Morgan Investment Management Inc. (“JPMIM”). GCP is a middle-market private equity investment firm based in New York. GCP has made investments in a number of industries, including tech-enabled business services, payments, and select financials. JPMIM is a U.S. registered investment adviser. Designees of GCP are members of the Board of Managers (the “Board”) of Verita’s ultimate parent company, KCC Parent LLC (“Parent”). Parent wholly owns Verita Intermediate, LLC, which in turn wholly owns Verita Global, LLC, which in turn wholly owns Verita Global Services, LLC, which in turn wholly owns Verita. One representative of JPMIM is entitled to attend and observe (but not vote) at all meetings of the Board, but no designee of JPMIM is a member of the Board.

11. Verita searched all entities listed in the list of Potential Parties in Interest against an internal database that includes (i) Verita’s parent entities, affiliates, and subsidiaries and (ii) GCP, GCP’s funds, and each such fund’s respective portfolio companies and investments as set forth in the list most recently provided to Verita by GCP. Based solely on the foregoing search, Verita has determined, to the best of its knowledge, that there are no material connections. JP Morgan Chase Bank, N.A. is listed as a bank on the Potential Parties in Interest List. There are information barriers between JPMIM and the line of business where JP Morgan Chase Bank, N.A. may be associated with the Debtors as a bank.

12. To the extent Verita learns of any other material connections between the funds or investments included in the above-described conflicts search and the Debtor, Verita will promptly file a supplemental disclosure. In addition, Verita may have had, may currently have, or may in the future have business relationships unrelated to the Debtors with one or more GCP or JPMIM entities including, among others, portfolio companies of GCP.

13. Verita has no contract or relationship with XClaim Inc. or with any other party under which Verita provides or will provide exclusive access to claims data and/or under which Verita will be compensated for claims data that is made available by Verita.

14. Verita has informed the Debtors that, subject to Court approval, it will invoice the Debtors at its standard hourly rates, which are set forth in the Services Agreement.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct to the best of my information, knowledge and belief.

Dated: January 8, 2026
Los Angeles, California

Respectfully submitted,

/s/ Evan Gershbein

Evan Gershbein
Executive Vice President
Kurtzman Carson Consultants, LLC dba
Verita Global
222 N. Pacific Coast Highway, 3rd Floor
El Segundo, California 90245
Telephone: (310) 823-9000

Exhibit 1

Potential Parties in Interest

Debtors

Apple Tree Life Sciences, Inc.
ATP Life Science Ventures, L.P.
ATP III GP, Ltd.
Apertor Pharmaceuticals, Inc.
Evercrisp Biosciences, Inc.
Initial Therapeutics, Inc.
Marlinspike Therapeutics, Inc.
Nine Square Therapeutics, Inc.
Red Queen Therapeutics, Inc.

Banks

Banc of California
Citizens Bank
Eastern Bank
JP Morgan Chase Bank, N.A.
Western Alliance Bank

Vendors

AAAS
BioCentury, Inc.
Boston Globe Life Science Media
Canon
Digital Science & Research Solutions, Inc.
DirectUS
Integration Appliance, Inc.
Petra
Prendio LLC
Private Plane Expenses

Consultants

Andrew Bayliffe
CBIZ Advisors, LLC
Grant Thornton LLP
Hughes and Hughes Bookkeeping
Newfront Consulting
Ollie Yuav

Contract Counterparties

1Password
American Copy Machines
BCL Search

Citeline
Directus Cloud
EndPointsNews
Evaluate Ltd.
Guidepoint Global, LLC
Insperity
Intapp
Massachusetts Medical Society
New England Journal of Medicine
Nextiva
Palmier Services Ltd.
Peta Funds Group
Science AAAS
Sentient Jet
Springer Nature
Rockefeller University Press Journal of
Experimental Medicine
The New York Times

Lessors

Contemporary Information Company
RXR HB Owner, LLC
230 Park Avenue Holdco, LLC

Utilities

8x8
Spectrum
Verizon

Insurance Providers

Coalition Insurance Solutions, Inc.
Continental Casualty Company
Federal Insurance Company
Houston Casualty Company
National Union Fire Insurance Company of
Pittsburgh, Pa
Travelers Excess and Surplus Lines
Company
Westfield Insurance Company

**Bankruptcy Judges, Court Staff, and
Clerk of Court for the District of
Delaware**

Chief Judge Karen B. Owens
Judge John. T. Dorsey
Judge Craig T. Goldblatt
Judge Thomas M. Horan
Judge Brenden L. Shannon
Judge Laurie Selber Silverstein
Judge Kate J. Stickles
Judge Mary F. Walrath
Al Lugano
Amanda Hrycak
Cacia Batts
Claire Brady
Danielle Gadson
Demitra Yeager
Jill Walker
Laura Haney
Laurie Capp
Lora Johnson
Marquetta Lopez
Nickita Barksdale
Nikki Washington
Paula Subda
Rachel Bello
Stephen L. Grant
Xavier Hunt

**Staff of the Office of the United States
Trustee, Region 3**

Andrew R. Vara
Benjamin Hackman
Christine Green
Denis Cooke
Diane Giordano
Dion Wynn
Edith A. Serrano
Elizabeth Thomas
Fang Bu
Hannah M. McCollum
Holly Dice
James R. O'Malley
Jane Leamy
Jonathen Lipshie
Jonathen Nyaku

Joesph Cudia
Joseph McMahon
Juliet Sarkessian
Lauren Attix
Linda Casey
Linda Richenderfer
Micheal Panacio
Nyanquioi Jnoes
Ramona Harris
Richard Schepacarter
Rosa Sierra-Fox
Shakima L. Dortch
Timothy J. Fox, Jr.

Board Members

Seth Harrison
Margaret Bigelow

Debtors' Professionals

B. Riley Restructuring Services, LLC
Murphy & King
Potter Anderson & Corroon LLP
Quinn Emanuel Urquhart & Sullivan, LLP
Verita
Walkers Global

**Portfolio Companies (aka non-debtor
affiliates)**

Aethon Therapeutics
Ascidian Therapeutics (fka Pulsar Bio
Therapeutics)
Aulos Bioscience
Braeburn
Deep Apple Therapeutics
Galvaniz Therapeutics
Marengo Therapeutics
Nereid Therapeutics
Replicate Bioscience

-

**Apple Tree Life Sciences, Inc.; ATP Life
Science Ventures, L.P.; and ATP III GP,
Ltd. Top 20 Unsecured Creditors**

Belay Solutions, LLC
CBIZ, Inc.
Chelsea Technologies LLC

Cogent Communications, LLC
Echelon Fine Printing
Maples Group
Mark Mitchnick
Pluris Valuation Advisors, LLC
RXR HB Owner LLC
The Agency Worldwide
The Regents of the University of California
Berkeley
Wilson Sonsini Goodrich & Rosati, P.C.

ATP Life Science Ventures, L.P. Equity Holders

230 Park Avenue, Suite 2800, New York,
New York 10169
Aaron Kantoff
Anna Batarina
Danjie (Eva) Zhou
David McIntyre
Hamade Family Trust (dated 6/18/2003)
Jonathan Waldstreicher
Julie A. Gionfriddo
Les Pommes LLC c/o/ Apple Tree Ventures
Management LLC
Marie-Therese Afif
Paul Eisenberg
Rigmora Biotech Investor One LP
Rigmora Biotech Investor Two LP
Rob Armstrong
Sally Jacob
Samuel Hall
Seth L. Harrison
Stephen G. Dance
The Lauren A. Farrell Trust (dated
5/18/2018)
William Engels

ATP III GP, Ltd. Equity Holder

Seth L. Harrison, MD

Red Queen Therapeutics, Inc. Top 20 Unsecured Creditors

Altasciences Company Inc.
Dechert LLP
Omega Systems Consultants

Omnicia, Inc.
Pace Analytical Life Sciences, LLC
Prendio LLC
Sarah Recchio
Wilson Sonsini Goodrich & Rosati, P.C.

Red Queen Therapeutics, Inc. Equity Holders

Dana-Farber Cancer Institute, Inc.
Gregory Bird
Henry Herce
Loren Walensky
Marilynn Bersoff
Mark Mitchnick
Namrata Turaga
Paul Da Silva Jardine
Paul Eisenberg
Ravneesh Sachdev
Spiros Liras

Red Queen Therapeutics, Inc., Creditors

1Life Healthcare Inc.
9375-3408 Quebec Inc.
ADP, Inc
Amnet Systems LLC
Apple Tree Life Sciences, Inc.
Aptar Congers
Arthur J. Gallagher Risk Management
Services, Inc.
Aruna K. Subramanian
Ascidian Therapeutics, Inc.
ATP Research and Development, Inc.
Bachem Americas, Inc.
Bay Valuation Advisors, LLC
BDO USA, LLP
Bend Financial, Inc.
Bill.com
Blue Cross Blue Shield
Boston Industries, Inc.
Brex
Browne Consulting Group
Cambridge Biolabs
Cambridge Trust
Cameron Wolfe
CD Chunn & Associates, Inc.
Charles River Laboratories, Inc.

Chien-Te Kent Tseng
Colorado State University
CPC Scientific, Inc.
Creative Biolabs Inc.
Credit Card Misc.
CT Corporation
Custom NMR Services, Inc.
Cytel Inc
Davey Smith
Delaware Secretary of State
Digital Insurance LLC
DocuSign, Inc.
Ea Spry Co. Inc.
eCtd Publishing LLC
Eric Smith
Eurofins Panlabs Discovery Services
Taiwan, Ltd.
Eurofins Panlabs Inc
Eva Garland Consulting
EyeMed
Fragomen, Del Ray, Bernsen & Loewy, LLP
Franchise Tax Board
Gyros Protein Technologies
Halloran Consulting Group
Hansol Jang
Human Predictions LLC
ImQuest BioSciences
InCSD, LLC
Integral Molecular, Inc.
Intuit
IVEK Corporation
Janet Nokleby
John George McHutchison
JTR & Associates, LLC
K P'Das Bio-Consulting
KOC Consulting, LLC
Kyinno Biotechnology Co., Ltd.
Larry Smith
Latham BioPharm Group
LinkedIn Corporation
Loxley LLC
Lyrica Therapeutics, Inc.
M3 USA Corporation
MED Regulatory & Toxicology Consulting,
LLC
Medizinische Universität Innsbruck
Meeting Protocol Worldwide LP
Meeting Protocol Worldwide LP-1
Microbiologics
NAGASE Specialty Materials NA LLC
Nanopharm Ltd.
Nanopharm Ltd. – USD
Next Breath
Organix
Peak Scientific Inc.
Pentagram Design Inc.
PPD Development, LP
ProPharma Group LLC
Protein Technologies, Inc.
Prudence Ciardullo
PurePEG, LLC
Quality Compliance Partners, Inc.
Raphael J. Landovitz
Retrovirox Inc.
RG Supply Chain Consulting Inc
Ron Moss
Shelterpoint
Shyam Kottlil
Sigmovir Biosystems Inc.
Sino Biological US Inc.
Solium Capital LLC
Southern Research Institute
Spences Services LLC
Sterling Corporation
Sun Life
The Agency Worldwide
The Catalytic Agency, LLC
Tremaine DMPK Consulting, LLC
True North Biopharm LLC
TS Pharma Experts LLC
Tufts Biolabs
University of Tennessee Health Science
Center
Uppsala Monitoring Centre
Utah State University, Institute for Antiviral
Research
V4Scientific
Vascumab LLC
Vectura Ltd.
ViraTree LLC
Vivitide
Waters Technologies Corporation

WilliamsMarston LLC
World Courier Inc
World Customs Brokerage Inc
WuXi AppTec (HongKong) Limited
YIN HTWE
Zahra Fathi

Initial Therapeutics, Inc. Top 20

Unsecured Creditors

Airgas USA, LLC
Armanino Advisory LLC
BDO USA LLP
CAS Chemical Abstract Services, Inc.
Curia Global, Inc.
Diamond Age Data Science LLC
Fisher Scientific Company, LLC
Forkable
Formulatrix LLC
Life Technologies Corporation
Mettler-Toledo Rainin, LLC
NexusCW Inc
Pegasus Purchaser, Inc.
Pharmaron, Inc.
Promega Corporation
ProteinSimple Checking BIN #39
Stemcell Technologies Inc
Tecan U.S. Inc
VWR International, LLC
Wilson Sonsini Goodrich & Rosati, P.C.

Initial Therapeutics, Inc. Equity Holders

Alexander McCampbell
Brain Paegel
Brooke Olsen Blair
Danielle Carino
Fred Ward
Ilsa Kirby
James H. Doudna Cate
James and Jennifer Doudna Cate Living
Trust (dated 1/2/2014)
Kevan Shokat
Kevan M. Shokat and Deborah Kamali, as
trustees of the Shokat-Kamali Living Trust
(dated 5/11/2012)
Margot Paulick
Mariwil Wong

Matthew Jacobson
Micheal Ehlers
Mohan Sivaraja
Mohit Trikha
Neena Kadaba
Peiwen Yu
Peter DiLaura
Phil Patten
Rachel Green
Rajesh Chopra
Sarah Smith
Spiros Liras
Stephanie Maiocco
Xiaoyue (April) Chen

Initial Therapeutics, Inc., Creditors

1Life Healthcare, Inc.
201 Spear Street
AA BLOCKS, LLC
AABC Testing & Certification
AACR
ABBEXA
Abcam, inc.
AC Hotel
AC Lab Instruments
Ace Parking
Acrotien ChemBio Inc
ACTenviro
Adobe
ADP
Agilent Technologies, Inc.
AIR-TITE Products Co., Inc.
AK Scientific, Inc.
Alaska Airlines
Alex's Mobile Notary Public Services
Alitheia Genomics SA
Allucent US LLC
Alpha Teknova, Inc.
Amami San
Amaresh Keleta
Amazon
Amazon Business Prime
Amazon Capital Services, Inc.
Amazon Web Services
Ambeed, Inc.
American Association for Cancer Research

American Chemical Society
 American Type Culture
 American Type Culture Collection
 Amith Vikram Rangarajan
 Amoura Resturant
 Ampersandpeople inc
 Anecdote
 Anirban Datta
 Ann MacLaren
 Antibodies Inc.
 AnytimeLabTrader, LLC
 Aon Consulting, Inc. (NJ)
 Apconix Ltd.
 Apertor Pharmaceuticals Inc.
 Apexbio Technology LLC
 Apicells Inc.
 Are Café Resturant
 Arthur Dean Olson (Dean Olson Patent Consulting)
 Arthur J. Gallagher Risk Management Services, Inc.
 Asana
 ASCO
 AstaTech Inc.
 Astrill VPN
 ATCC
 ATP Research and Development, Inc.
 Atum
 Aurigene Pharmaceutical Services, Ltd.
 Avanan
 Aviva Systems Biology
 Axis Enterprises Inc.
 Axis Promotions
 Azenta US, Inc.
 Backhaus
 BambooHR
 Baskin-Robbins
 Bay Valuation Advisors
 Bayshore Safety & Industrial Supplies
 BCBS
 Beckman Coulter, Inc.
 Becton, Dickinson & Co.
 Bend Financial
 Biocom California
 BioDuro LLC
 BioIVT
 BioLegend
 BioProcedure
 Bio-Rad Laboratories, Inc.
 Biospace
 Biotage, LLC
 Biotech Equipment Sales, Inc.
 Bio-Techne Sales Corporation
 Bliss Pops
 Blossom Flower Deliver
 Blue Bottle Coffee
 BMG LABTECH, Inc.
 Bordelon Marine
 Boster Biological Technology
 Box, Inc.
 BPS Bioscience Technology
 Brady Worldwide Inc
 Brex Card – Expensify Linked
 Brian Benjamin Tuch
 Bridge Bank
 Broken Yolk Café
 Bronwyn Sanders
 Browne Consulting Group
 BUTCHER’S CUT
 Cable 55
 Caffe Central
 Caffe Centro
 California Chamber of Commerce
 California Franchise Tax Board
 California Pizza Kitchen
 Cambridge Healthtech Institute
 Cancer Research Institute
 CC My Admin LLC
 CDW LLC
 Celine Calalang
 Cell Culture Company
 Cell Signaling Technology, Inc.
 Certara USA, Inc.
 Certified GeneTool, Inc.
 Champions Oncology, Inc.
 Charles Kreider (Kreider Consulting)
 Charles River Laboratories
 Chase Luck Bakery
 Checkr
 ChemAxon
 ChemExplorer Company LTD
 Chemglass Life Sciences

Chemical Computing Group
Chemrus Inc.
Che,scene Limited Liability Company
Chemtos LLC
Chico Marx
Chipotle Online
Christine Matthews (now Digital Insurance)
Christos Tzitzilonis
Chwen Cheng Chen
Cintas Corporation (AZ)
City of Burlingame
City of Sm Pw Parking
City of South San Francisco
City of Ssf Permit Dept
Clarke Consulting
Clarke S1 Sirm
Clipper
CLSA
CAN
Collaborative Drug Discovery, Inc.
Combi-Blocks Inc.
Computer Care
Copyright Clearance Center
Corovan Moving & Storage Co.
Costco
Creative Biogene, Inc.
Creative Biolabs, Inc.
Credit Card Misc.
Crossmint Pending
Crown Bioscience Netherlands BV
Crown Bioscience, Inc.
Crown Worldwide Moving and Storage,
LLC
CSC
CSC Leasing CO
Cshl Meetings & Courses
CT Corporation
Culligan
Culligan Water
Curia Bio Inc. (dba Lake Pharma)
Cursor
CVS Pharmacy
Daicel Chiral Technologies
Danae Inc.
Daniel W Pierce
Data Kable Technology Inc
Dataworks Development Inc
DC3 Therapeutics, LLC
De Novo Software
Dead Eye Coffee Bar
Dean W. Felsher
Deep Apple Therapeutics, Inc.
Delaware State
DeNoix Inc
DHL
Diaago LLC
Dice Molecules SV, inc.
Divisadero Florist
DocuSign
Dojindo Molecular Technologies, Inc.
Dollar Tree
Donald Schmidt Jr.
DoorDash
Dorothy Rachel Green
Dotmatics, LLC
Dragonfly Design Group
Drug Design Group
Easy Learning Incubator LLC
EasyLlama
Eataly
eBay
EDITCO BIO INC.
Edward M. Driggers
Eirna Bio Ltd
Embassy Suites by Hilton
EMD Millipore Corporation
Emily Lin Karbarz
eMolecules, Inc.
Enamine US Inc.
Endpoints
Envoy
Eppendorf North America Inc.
Esposito's Catering
Esquire
Esraa Mohamed
Etsy
Eurofins Cerep SA
EUROFINS DISCOVEREX CORP
Eurofins Panlabs Inc.
EventCreate
Express Parking
Extra Space Storage

EyeMed
ezCater
Ezccater Ruse Woodfire
Farley's
FedEx
FlowJo LLC
Fragomen, Del Ray, Bensen, & Loewy, LLP
Frontage Laboratories, Inc.
Frontier Scientific Services Inc.
Fuchunju
FUJIFILM Wako Chemicals U.S.A.
Corporation
G&P Biosciences LLC
Galen Laboratory Supplies LLC
GarboBio Inc. (AcceGen)
Gary F. Musso
Gaslamp
GeneCopoeia, Inc.
Genesee Scientific Corporation
GenScript USA, Inc.
Gifford Bioscience Ltd
Github
GlobalData
GoDaddy
Gordon Rees Scully Mansukhani, LLP
Grainger Industrial Supply
Grant Park Bistro
GraphPad
Greenhouse Software, inc.
GroupGreeting
GS Pharma Solutions, LLC
Hamamatsu Corporation
Headline Pa
Herb N' Kitchen
High Flying Foods
Hilton Hotels
HL Peninsula
HoneyBaked Ham
Horizon Discovery Biosciences Ltd
Hyatt
Ichika Sushi House
IKA-WORKS, Inc.
IKEA
Il Fornaio
Illumina, Inc.
Impark
India Quality Restaurant
Indian Clay Pot
Instacart
Integra Biosciences Corporation
Integrated DNA Technologies, Inc.
Integrative Drug Discovery ULC
Intuit
Invested Digital Group, Inc.
IQ Proteomics, LLC
Jack in the Box
Jackie McGrath Inc.
Jeff Hsu
Jena Bioscience GmbH
Jennifer Rocnik
Jessamyn Wead
Jetbrains Americas, Inc.
Jim Li
JMP Group Inc.
John Hood
Jonathan R Wong dba Enigma Search
Solutions LLC
Joesph M. Llovet
Joesph Fan
Julius Khoo, Consultant
K.F. Howell Electric, Inc.
Kai Fa Qu Xi Lai Deng Jiu
Kenneth B. Wlasichuk
Kim F. McClure (Kb Pharma Consulting,
LLC)
Klein Hersh International
Kristina Leandra Harter
Kristine Anne Gordon
Laurie L. LeDoux
LAZ Parking
Leibniz-Institut DSMZ-Deutsche Sammlung
von Mikroorganismen und Zellkulturen
GmbH
Lenovo Group
Letterman Digital Arts
LifeSpan Biosciences, Inc.
Lonza Walkersville, Inc.
Lowe's
Lucid Software
Luke's Lobster
Marriott
Marshall Scientific LLC

| | |
|---|--|
| Martin S. Linsell | On The Roll Catering and Events |
| Maruzen International Co., Ltd. | One12 |
| Matphil Technologies, Inc. dba Pipette.com | OneDigital Topco LLC (Digital Insurance LLC) |
| McCormick Place | OpenAI |
| McMaster-Carr Supply | Optibrium Limited |
| McNeill Baur PLLC | OriGene Technologies, Inc. |
| Meaghan An | Osteria Panevino |
| MeCour Temperature Control, LLC | Palace Hotel Dining |
| MedChemExpress LLC | Panera Bread |
| Mercury Business Services LLC | Parking – SF |
| Meso Scale Diagnostics, LLC | Parr Instrument Company |
| Metrion Biosciences Ltd. | Pbss |
| Mzez Greek Fusion | Penske Truck Rental |
| Microsoft Office Azure | PerformYard, Inc. |
| Microsoft Store | Peter DiLaura |
| Miller & Lux Restaurant | Pharmablock (USA), Inc. |
| MingHin Cuisine | Phenomenex, Inc. |
| Molecular Devices, LLC | Pingyu Ding |
| MongoDB | Pizzeria Delfina |
| Monnit Corporation | Plasmidsaurus Inc. |
| Moravek Biochemicals, Inc. | Posit Software, PBC |
| Morrow Service, Inc. | Postal Annex |
| Mosaic Networx, LLC | Prendio LLC |
| Murigenics, Inc. | Pressed Café |
| Murphy & King | Prestige Lens Lab |
| MyBioSource, Inc. | PricewaterhouseCoopers LLC |
| NanoImaging Services, Inc. | Primordium Labs |
| Nanosyn, Inc. | Prince Scientific LLC |
| National Screening Services LLC | Profcontrol GmbH |
| Nationwide Screening Services | Pronto! |
| Nespresso | Proteintech Group, Inc. |
| New England Biolabs | Qiagen LLC |
| Nicholas Galli | Quintara Discovery, Inc. |
| Nine Square Therapeutics Corporation | R&D Systems, Inc. |
| Niu B | Rachel Kindt |
| NorCal Water | Ramen Hero |
| Nothing Bundt Cakes | RayBiotech |
| Novogene Corporation Inc. | RC TRITEC AG |
| NovoPro Bioscience Inc. | Regents of the University of CA, Irvine |
| Novus Biologicals, LLC | Remarkable |
| Nuaire | RevMAB Biosciences USA, Inc. |
| NXT Power, LLC | Revvity Health Sciences, Inc. |
| Occupational Health Centers of North Carolina, P.C. | Revvity Signals Software, Inc. |
| Okta, Inc | Rhino Networks |
| OLIVAS MEXICAN FOOD | Ribomaps LTD |

| | |
|---|--|
| Ricky P Jones | Staples |
| RIPOSO | Staples Advantage |
| Riposo Mobile | Starbucks |
| Road Master Club | Stella Alpina Osteria |
| Ronnie-Ray Abriam Orpilla | Stericycle, Inc. |
| Rosemarie O'Shea | Steven A Smith |
| RStudio | Steven J. Freedman |
| Rudra Nand | Steven R. Sando |
| Russell Reynolds Associates, Inc. | Strategic Spaces |
| Sab Lai Thai Kitchen | Subscription Cc Auth |
| Samuel Munroe | Sun Life Financial |
| San Diego Convention Center | Surplus Solutions LLC |
| San Francisco Baking Institute | Susan Lyman |
| San Francisco International Airport | Susanne Steggerda |
| San Mateo County | Swagelok Northern California |
| San Mateo County Tax | Synthego Corporation |
| Santa Cruz Biotechnology Inc | System Biosciences |
| Sartorius Corporation | TAQUERIA LAS PENCAS |
| SBC Worldwide, LLC | Target |
| Schrodinger | Tastes On The Fly |
| SciSummary | Tax1099 |
| Secretary of State California | TeamViewer |
| See's Candies | Technical Safety Services, LLC |
| Seismic Installations | Technology & Patent Research |
| Selleck Chemicals LLC | International, Inc. |
| Sensitech Inc. | Teledyne ISCO |
| Sentinel | Thai Satay Restaurant & Bar |
| Seqmatic LLC | The Agency Worldwide |
| SFMTA Parking | The Catalytic Agency, LLC |
| Shanghai Chempartner Co., Ltd. | The Cohen Group |
| Sheridan Books | The Grove Wine Bar & Kitchen - Cedar |
| Shisan Fan Sushi and Chinese Restaurant | Park |
| Shred City | The Home Depot |
| Sigma-Aldrich, Inc. | The Honest Company |
| Signal Solutions Corporation | The Regents of the University of California, |
| Silicon Valley Corporate Relocation | San Francisco |
| SL 2T, LLC (SmartLabs) | The Speech Improvement Company Inc. |
| Slack | Therma LLX |
| Slidexpress PVT LTD | Thomas Scientific Holdings Inc |
| SmartSign | Thorlabs, Inc. |
| SnapGene | Tim French |
| SNPsaurus | Total Winne & More |
| Solium Plan Managers LLC | Traverse |
| Soloprotect US | TriLink Biotechnologies, LLC |
| SPRO | Trip.com |
| Stanford University | Triton Appliance Repair |

Uber
Uline, Inc
United
Unity Biotechnology
University of California, San Diego Small
Molecule X-ray Crystallography Facility
UPS Supply Chain Solutions, Inc.
Urban Kitchen
USA Scientific, Inc.
USPS
Vector Laboratories, Inc.
Veloxee
Vincor Tech
Vistaprint
W.B. Mason Company, Inc.
W.W. Grainger, Inc.
Waterco of California
Wave
Wave Rock
West Coast Chemistry Services
White Elephant Restaurant
Whole Foods Market
Williams Marston
Wise Guys Events
WPP Group USA, Inc. dba Ogilvy Health
WTMR
WuXi AppTec (Shanghi) Co., Ltd.
Yi Chao Fan
Yummy Home Plate
Zachary Sweeney (Edgewood Scientific
Consulting)
Zazzle
Zoom Video Communications, Inc.
Zotero
Zymo Research Corporation

**Marlinspike Therapeutics, Inc. Top 20
Unsecured Creditors**

Advion, Inc.
Air Systems Technologies Inc
Aurigene Pharmaceutical Services LTD
Baylor College of Medicine
BDO USA, LLP
BioProcure, Inc.
Biotech Law Center, Inc.

Browne Consulting Group
Crown Castle International Corp.
CSC Leasing Co
Digital Insurance, LLC
Middlesex Gases & Technologies, Inc.
Norton Rose Fulbright US LLP
Pharmaron, Inc.
PPF OFF 150
Roger Benjamin Ruggeri
Safety Partners
Triumvirate Environmental, Inc.
Viva Biotech (Shanghai) Limited
Wilson Sonsini Goodrich & Rosati, P.C.

**Marlinspike Therapeutics, Inc. Equity
Holders**

Alessandro Boezio
Alexander McCampbell
Baylor College of Medicine
Calla Olson
Joesph Yanchik
Kristen Karlin
Paul Da Silva Jardine
Rajesh Chopra
Thomas Westbrook
Victor Rusu

**Apertor Pharmaceuticals, Inc., Top 20
Unsecured Creditors**

1640 South Loop Road LLC c/o Paceline
Investors LLC
Alameda County Tax Collector
Benchling, Inc.
BioDuro, LLC
BioProcure, Inc.
Browne Consulting Group
Cell Signaling Technology, Inc.
Clarke Consulting, Inc.
CSC Leasing Company
De Lage Landen Financial Services, Inc.
Digital Insurance, LLC
Elsevier B.V.
IQ Proteomics, LLC
Laboratory Equipment Company
Life Technologies Corporation
Reaction Biology Corporation

Science Suite Inc. dba BioRender
University of North Carolina at Wilmington
Wilson Sonsini Goodrich & Rosati, P.C.
Zhejiang Huida Biotech Co., Ltd.

Apertor Pharmaceuticals, Inc. Equity Holders

Bo Pang
Daniel Nomura
Edmund Graziani
Ericka Mendez
Jay Keasling
Jay D. Keasling Trust (Dated 8/5/2013)
Kevan Shokat
Lawrence Lum
Matthew Jacobson
Micheal White
Neena Kadaba
Paul De Silva Jardine
Paul Eisenberg
Paul Hawkins
Rajesh Chopra
Samantha Bucktrout
Shellwater & Company
Spiros Liras

Apertor Pharmaceuticals, Inc., Creditors

ILife Healthcare, Inc.
Abcam, Inc.
Abmole Bioscience Inc.
Abwiz Bio Inc
Access Plants LLC
Adams & Chittenden Scientific Glass
ADP
Advanced Chemical Transport
Agilent Technologies, Inc
AK Scientific, Inc.
Alameda County Environmental Health
Amazon Capital Services
Amazon Web Services
Ambeed Inc.
AmiD Biosciences LLC
AnaSpec Inc.
Apple Tree Life Sciences, Inc.
Applied Chemistry Solutions
Applikon Biotechnology, Inc.

Arash Samadi
Arthur J. Gallagher Risk Management Services, Inc.
ATCC
Atlas Copco Compressors LLC
ATP Research and Development, Inc.
Avanan, Inc
AxisPharm
Azenta US, Inc.
Bay Air Systems
Bay Valuation Advisors, LLC
BCBS MA
BDO USA, LLP
Becton, Dickinson and Company
Bend Financial, Inc.
Bill.com
Bio Basic Inc.
bioauxilium
Biocair Inc
BioLegend, Inc.
Biomatik Corporation
BioPharmics LLC
Bio-Rad Laboratories, Inc.
Biotage LLC
BiotechnologyJobs
Biozilla, LLC
Bordelon, Inc dba Ben's Dry Ice
Boston BioProducts, Inc.
BPS Bioscience, Inc.
Brex
BroadPharm
BUCHI Corporation
California Fire Detection
California Life Sciences
Carvill Consulting
Cayman Chemical Company Inc.
CC My Admin, LLC
CDW Direct, LLC
Cell Biolabs, Inc.
Charles River Discovery Research Services UK Limited [GBP]
Charles River Discovery Research Services UK Limited [USD]
Charles River Laboratories Cell Solutions, Inc.
Chemglass Life Sciences, LLC

Chemical Computing Group
Christian Puccetti
Chun Li
Cintas Corporation
Clarivate Analytics (US) LLC
Clark + Elbing LLP
CNA
Cole-Parmer Instrument Company, LLC
Collaborative Drug Discovery, Inc.
Combi-Blocks Inc.
Comcast
Commonwealth of Massachusetts
ComputerCare, LLC
Cooley LLP
Copyright Clearance Center, Inc.
CozChemix Limited
Creative Bioarray
Creative BioMart Inc.
Credit Card Misc.
CT Corporation
CTK Instruments LLC
Data Kable Technology Inc
Dean Olson Patent Consulting LLC
Demetrix, Inc.
Denisse Martinez
Diaago LLC
Diego Garrido Ruiz
Discovery Life Sciences
Discovery Scientific Solutions LLC
Diversified Laboratory Repair, Inc.
Dragonfly Design Group, Inc.
E-Control Systems, Inc.
Elson Electric
Epoch Life Science, Inc.
Eppendorf North America, Inc.
Esco Technologies, Inc.
EyeMed
Fahim Syed
FedEx Freight
First Choice Coffee Services
Fisher Scientific
Flowjo, LLC
Fortis Life Sciences fna Bethyl Laboratories
Foxy Life Sciences, LLC
Fragomen, Del Ray, Bernsen & Loewy, LLP
FUJIFILM Wako Chemicals U.S.A.
Corporation
Genesee Scientific Corporation
Genewiz, LLC
Genprice Inc.
GenScript USA Inc.
Gentige USA Sales, LLC
Global Industrial
Global Life Sciences Solutions USA LLC
Gold Biotechnology
Gordon Research Conferences
Grainger
GSL Biotech, LLC
Hamilton Company, Inc.
Harris & Lee Environmental Sciences LLC
HARVARD APPARATUS
Heather Roth
Hooke Laboratories, Inc.
HIS
ICE Safety Solutions
IKA Works, Inc.
Independent Plumbing Co.
Infors USA Inc.
Ingenium Group, LLC
Initial Therapeutics, Inc.
Integra Biosciences Corporation
Integrated DNA Technologies, Inc.
Intuit, Inc
Invested Digital Group, Inc.
Iron Box LLC
Isomerase Therapeutics Ltd
James Kim
Jeff Wong
Jeremy Barton Consulting Inc.
Karen Sutherland
KBA Document Solutions, LLC
Kelly Services
Labelmaster
LABRepCo LLC
Lambda
Lawson Drayage, Inc
Leibniz- Institut DSMZ-Deutsche
Sammlung von Mikroorganismen und
Zellkulturen GmbH
Leo Letendre
LHE Bioscience Inc.

| | |
|---|--|
| LI-COR Biotech, LLC | ProPharma Group LLC |
| LI-COR, Inc. | Proskauer Rose LLP |
| Linde Gas & Equipment Inc. | Protection Plus Security Services |
| Litmos US, L.P. f/k/a Solo Operations US, LLC | Proteintech Group, Inc. |
| Lonza Walkersville, Inc. | Qiagen LLC |
| Mallory Safety and Supply LLC | QuakeHold Industrial, Inc. |
| Marmon Biostatistics | R&D Systems, Inc. |
| Marvelgent Biosciences, Inc. | Rabin |
| McMaster-Carr | Raissa Estrela Curado |
| MedChemExpress, LLC | Ray Liu Consulting LLC |
| MedSupply Partners | Regina Roodhouse |
| Mettler-Toledo Rainin, LLC | Revvity Health Sciences, Inc. |
| Mettler-Toledo, LLC | Revvity Signals Software, Inc. |
| Microverse Studios | Roman Aguirre |
| Molecular Devices | Rose Citron |
| Mosaic Network | San Mateo County Tax Collector |
| Nacalai USA, Inc. | Sandra Santulli-Marotto |
| Naomy Jareily Ruvalcaba | Santa Cruz Biotechnology, Inc. |
| National Institute of Technology and Evaluation | SBS Pharma Consulting |
| Nationwide Screening Services | Sciencelo |
| NBS Scientific, LLC | Scientific Plastics Company, Inc. |
| NCS Moving Services | SciSafe Inc. |
| Nefeli Chanoutsi | Seismic Installations |
| Neil Vasan | Sentinel Benefits |
| New England BioLabs, Inc. | SeqCenter |
| New Life Scientific, Inc. | SEQUETECH CORP |
| New Pig Corporation | Sequoia Signs & Graphics, Inc. |
| Nine Square Therapeutics | SFS Chemical Safety |
| North America Immigration Law Group | Shimadzu Scientific Instruments, Inc. |
| Novogene Corporation Inc. | Shinji Kasahara |
| Novus Biologicals, LLC | Sigma-Aldrich, Inc. |
| NW Seacology | Signalchem Biotech Inc. |
| NXT Power | Signosis, Inc. |
| Okta, Inc. | Silas Burdick |
| OTJ Architects | Sino Biological US inc. |
| Oxford Nanopore Technologies Inc. | SL2T LLC |
| Peak Scientific, Inc. | SmartSheet Inc. |
| Pete KOH Installations | SNPsaurus LLC |
| Phenomenex, Inc. | Solium Plan Managers LLC |
| Plasmidsaurus | SoloProtect US LLC |
| Prenido LLC | South San Francisco Fire Department |
| Prestige Lens Lab | Southern Biotech |
| PricewaterhouseCoopers LLP | Staples Advantage |
| Promega Corporation | State of CA – Franchise Tax Board |
| | State of Delaware – Division of Corporations |

Stemcell Technologies Inc
 STERIS Corporation
 Strategic Spaces, LLC
 STRUCTURAL ENGINEERS, INC.
 Sun Life Assurance Company of Canada
 Takara Bio USA, Inc.
 Technical Safety Services, LLC
 Teco Pneumatic
 Tenova Pharmaceuticals Inc.
 Thames Pharma Partners, LLC
 The Cambridge Crystallographic Data
 Centre
 The Cohen Group
 The Ogilvy Group LLC
 The Regents pf the University of California
 Thermo Fisher Financial Services Inc.
 Thomas Scientific, LLC
 Tinghua Cao
 Toronto Research Chemicals, Inc.
 Tracking Solutions, Inc.
 Twist Bioscience Corporation
 Uline, Inc.
 US Bank Equipment Finance
 USA Scientific
 Varigen Biosciences
 Vascumab LLC
 Veolia Water Technologies, Inc.
 VWR International LLC
 William A. Faubion, M.D.
 WilliamsMarston LLC
 Wuxi AppTec (HongKong) Limited
 Wynden Stark LLC
 XanTec bioanalytics GmbH
 Zymo Research Corporation

Evercrisp Biosciences, Inc. Top 20

Unsecured Creditors

Admera Health, LLC
 Agilent Technologies, Inc.
 BioMetas Group Limited
 Browne Consulting Group
 Charles River Laboratories, Inc.
 ChemPartner Corporation Chengdu
 ChemPartner Co., Ltd.
 CSC Leasing Company
 Digital Insurance, LLC

Fisher Scientific
 Global Project Partners, LLC
 Horizon Discovery Biosciences Ltd
 Jennifer Doudna
 Life Technologies Corporation
 Marija Zecevic
 Pegasus Purchaser Inc., - BioProcure LLC
 Robert Thomas Abraham
 Tanja Kortemme
 VWR International, LLC
 Wilson Sonsini Goodrich & Rosati, P.C.
 Wuxi AppTec (HongKong) Limited

Evercrisp Biosciences, Inc. Equity

Holders

Ajeeth Adhikari
 Benjamin Jagger
 Brian Vash
 Cody Krivacic
 Geoffrey Berguig
 Jennifer Doudna
 Matthew Jacobson
 Meenu Karson
 Neena Kadaba
 Peng Cheng Zhang
 Raj Chopra
 Robert Abraham
 Stephanie Maiocco
 Steven Strutt
 Spiros Liras
 Tanja Kortemme
 Victor Rusu

Nine Square Therapeutics, Inc. Top 20

Unsecured Creditors

Amazon Web Services
 Amprion, Inc.
 Biognosys AG
 Browne Consulting Group
 CAS
 Cell Signaling Technology, Inc.
 FUJIFILM Cellular Dynamics, Inc.
 Hooke Laboratories, LLC
 Institut Curie
 LeadTech Pharma, Inc.
 Life Technologies Corporation

Mettler-Toledo Rainin, LLC
Pegasus Purchaser, Inc. (BioProcure)
Pharmaron
PLANET PHARMA, LLC
Regents of the University of Michigan
Revvity Health Sciences, Inc.
Viva Biotech (Shanghai) Limited
Wilson Sonsini Goodrich & Rosati PC
Wuxi AppTec United

Nine Square Therapeutics, Inc. Equity

Holders

Aimee Kao
Alexander McCampbell
Brina Le
Chakrapani Kalyanaraman
Damoder Motati
Hoi-Shan (Helen) Wong
Jacob Meller Eriksen
James Summers
John Hood
Kristine A. Gordon
Lani Wu
Louise Heinrich
Mark Rosen
Matthew Jacobson
Micheal Ehlers
Neena Kadaba
Paul Da Silva Jardine
Robert Edwards
Robert Paul
Roberto Zoncu
Sami Barmada
Samuel Clark
Sarah Smith
Spiros Liras
Steven Altschuler
Tetsuya Kobayashi
Tina Schwabe

Rigmora LPs

Rigmora Biotech Investor One LP
Rigmora Biotech Investor Two LP